Ameritas Investment Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Ameritas Investment Partners’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31.8K	Sell	5,914 -1,600	-21%	-$7.35K	﹤0.01%	2359
2025 Q4	$26.8K	Hold	7,514	–	–	﹤0.01%	2504
2025 Q3	$21.8K	Hold	7,514	–	–	﹤0.01%	2617
2025 Q2	$27.1K	Hold	7,514	–	–	﹤0.01%	2525
2025 Q1	$22.5K	Hold	7,514	–	–	﹤0.01%	2500
2024 Q4	$25.2K	Hold	7,514	–	–	﹤0.01%	2535
2024 Q3	$25.2K	Hold	7,514	–	–	﹤0.01%	2539
2024 Q2	$24.9K	Hold	7,514	–	–	﹤0.01%	2522
2024 Q1	$30.4K	Hold	7,514	–	–	﹤0.01%	2402
2023 Q4	$22.9K	Buy	7,514 +2,450	+48%	+$7.42K	﹤0.01%	2523
2023 Q3	$15.2K	Hold	5,064	–	–	﹤0.01%	2660
2023 Q2	$18.9K	Hold	5,064	–	–	﹤0.01%	2593
2023 Q1	$17K	Hold	5,064	–	–	﹤0.01%	2530
2022 Q4	$24.1K	Hold	5,064	–	–	﹤0.01%	2487
2022 Q3	$28K	Hold	5,064	–	–	﹤0.01%	2336
2022 Q2	$35K	Hold	5,064	–	–	﹤0.01%	2214
2022 Q1	$37K	Hold	5,064	–	–	﹤0.01%	2233
2021 Q4	$45K	Hold	5,064	–	–	﹤0.01%	2186
2021 Q3	$178K	Hold	5,064	–	–	0.01%	1290
2021 Q2	$109K	Buy	5,064 +3,849	+317%	+$116K	﹤0.01%	1674
2021 Q1	$75K	Hold	1,215	–	–	﹤0.01%	1828
2020 Q4	$51K	Buy	+1,215	New	+$39.2K	﹤0.01%	1979

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ameritas Investment Partners's AVIR Position: Q1 2026 in Review

Ameritas Investment Partners reduced its Atea Pharmaceuticals (AVIR) stake by 21% in Q1 2026, selling an estimated $7.35K and leaving 5,914 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Ameritas Investment Partners first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $178K in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Ameritas Investment Partners held 5,914 shares of Atea Pharmaceuticals worth $31.8K as of Q1 2026.
Ameritas Investment Partners sold 1,600 Atea Pharmaceuticals shares in Q1 2026, an estimated $7.35K.
Atea Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2359 holding.
Ameritas Investment Partners first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
Ameritas Investment Partners's Atea Pharmaceuticals position peaked at $178K in Q3 2021.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.